Novel insight into mitochondrial dynamin-related protein-1 as a new chemo-sensitizing target in resistant cancer

Samar Sami Alkafaas1, Omar K Obeid2, Mustafa Ali Radwan3

  • 1Molecular Cell Biology Unit, Division of Biochemistry, Department of Chemistry, Faculty of Science, Tanta University, 31527, Egypt.

Bioorganic Chemistry
|June 27, 2024
PubMed

Insights

Mitochondrial dynamics, regulated by Drp-1, are crucial in cancer progression and chemoresistance. Inhibiting Drp-1 shows promise for enhancing cancer treatment responsiveness.

Area of Science:

  • Cell Biology
  • Oncology
  • Biochemistry

Background:

  • Mitochondria play critical roles in cancer cell survival, influencing metabolism, calcium signaling, and ROS production.
  • Maintaining mitochondrial dynamics (fission/fusion balance) is vital for cellular bioenergetics and healthy cellular processes.
  • Dysregulation of mitochondrial dynamics, particularly involving Drp-1, is implicated in cancer progression, invasion, metastasis, and chemoresistance.

Purpose of the Study:

  • To review the role of Drp-1 in mitochondrial dynamics and its connection to cancer progression and chemoresistance.
  • To computationally assess publicly available Drp-1 inhibitors for their potential in cancer therapy.

Main Methods:

  • Literature review focusing on Drp-1, mitochondrial dynamics, and cancer.
  • Computational assessment of Drp-1 inhibitors.
  • Analysis of Drp-1's role in cancer invasion, metastasis, and chemoresistance.

Main Results:

  • High Drp-1 levels are observed in various cancers, correlating with invasion, metastasis, and chemoresistance.
  • Inhibitors like Mdivi-1 can enhance cancer cell sensitivity to chemotherapy.
  • Several novel compounds (Drp1-IN-1, Dynole 34-2, trimethyloctadecylammonium bromide, Schaftoside) demonstrated potent Drp-1 inhibitory effects compared to Mdivi-1.

Conclusions:

  • Targeting Drp-1-mediated mitochondrial dynamics presents a promising strategy for cancer management.
  • Further research is needed to develop effective Drp-1 inhibitors for improved cancer treatment outcomes.
  • This approach holds potential for enhancing cancer therapy and overcoming chemoresistance.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
12.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K